RSV Vaccine Slashes Infant ICU Admissions by 97%
A study published in JAMA Network Open shows that the nirsevimab immunization reduced infant ICU admissions for RSV by 97%. The findings support a universal approach to RSV prevention in infants.
Why it matters
Demonstrates the high efficacy of monoclonal antibody treatments in preventing severe respiratory illness in infants, potentially changing public health vaccination strategies.
A new immunization, offered free to all infants through universal programs in two Canadian provinces, provided strong protection against respiratory syncytial virus, commonly referred to as RSV, sharply reducing hospitalizations and intensive care unit (ICU) admissions in infants. The findings, published in JAMA Network Open, evaluated the real-world effectiveness of nirsevimab, a long-acting monoclonal antibody that gives infants ready-made antibodies to prevent severe RSV illness. The research was conducted by the University of Calgary - led Surveillance Program for the Rapid identification and tracking of Infectious Diseases in kids (SPRINT-KIDS).
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in